TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Managing Temporomandibular Disorder (TMD) Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* TMD Pain Diagnosis as determined by enrollment exam at the University of Washington~* Menstruate on a regular basis~* Not planning to become pregnant during the next 6 months~Exclusion Criteria:~* Drug or alcohol abuse~* Current smoker and 35 years of age at any time during the study~* Live further than 1 hour driving distance from the University of Washington, Seattle campus~* Psychiatric disability

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Self Management (Type: ACTIVE_COMPARATOR): Dental hygienist-delivered pain self-management treatment
- Targeted Self Management (Type: EXPERIMENTAL): Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
- Continuous Oral Contraceptives (Type: EXPERIMENTAL): Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have T2DM for at least 3 months before screening and are without advanced known possible complications of diabetes mellitus~* Have a glycated hemoglobin (HbA1c) value at lead-in and screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening~* Have had a stable body weight for the 3 months prior to randomization (\<5% body weight change)~* Have a body mass index of 23 to 50 kilograms per square meter (kg/m²), inclusive~* Male participants agree to use an effective method of contraception for the duration of the study plus 90 days, which corresponds to 4 months after the last investigational product dose~* Women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or those who are postmenopausal~Exclusion Criteria:~* Have type 1 diabetes mellitus or latent autoimmune diabetes in adults~* Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening~* Have a known clinically significant gastric emptying abnormality~* Have had an episode of severe hypoglycemia~* Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of \>500 milligrams per deciliter (mg/dL) at screening and/or Day-2. If participant is on lipid-lowering therapies, doses must be stable for 30 days prior to screening~* Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]) greater than 3X upper limit of normal (ULN) at screening and/or Day -2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LY3437943 (Type: EXPERIMENTAL): LY3437943 administered subcutaneously (SC)
- Dulaglutide (Type: ACTIVE_COMPARATOR): Dulaglutide administered SC
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Asian patients 50 years of age or greater.~* Patients with primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or active occult lesions with no classic component.~* Patients who have a BCVA score between 73 and 24 letters (approximately 20/40 to 20/320 Snellen equivalent), inclusively, in the study eye.~* Total area of CNV (including both classic and occult components) encompassed within the lesion must be \>= 50% of the total lesion area~* Total lesion area must be \<= 12 disc areas~Exclusion Criteria:~* Patients who have in the fellow eye a Snellen equivalent below 20/200~* Presence of angioid streaks, presumed ocular histoplasmosis syndrome, myopia (exceeding -8 diopters), or CNV secondary to causes other than AMD in the study eye~* Subfoveal fibrosis or atrophy in the study eye~* Total area of CNV (including both classic and occult components) encompassed within the lesion must be \>= 50% of the total lesion area~* Total lesion area must be \<= 12 disc areas~* Vitreous hemorrhage, retinal tear or history of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.~* Active, or history of, ocular inflammation or infection in the study eye within the last 30 days prior to screening.~* Uncontrolled glaucoma in the study eye~* Treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, submacular surgery, or transpupillary thermotherapy within 30 days prior to screening~* Previous treatment with anti-angiogenic drugs (pegaptanib, ranibizumab, bevacizumab, anecortave acetate, corticosteroids, protein kinase C inhibitors, squalamine, siRNA, VEGF-Trap etc.) for neovascular AMD in the study eye. Treatment of the fellow eye is permitted if administered \> 30 days before screening.~* History of intraocular surgery in the study eye including pars plana vitrectomy, except for uncomplicated cataract surgery more than 60 days prior to screening~* History of YAG laser posterior capsulotomy in the study eye within 30 days prior to screening

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria are as follows:~* Age: 16 - 80 years~* Subject is having a clinically indicated endoscopy for suspicious EoE and has been on twice daily (BID) proton pump inhibitor (PPI) for at least 8 weeks OR New diagnosis of EoE as per consensus guidelines. Cases must have symptoms of dysphagia, persistent esophageal eosinophilia (≥ 15 eosinophils in at least one high-power field) after 8 weeks of treatment with a twice daily proton-pump inhibitor, and other competing causes of esophageal eosinophilia excluded.~Exclusion criteria are as follows:~* Medical instability that precludes safely performing upper endoscopy~* Ongoing or recent symptoms of intestinal bleeding (throwing up blood, passing blood in the stool)~* Concomitant eosinophilic gastroenteritis~* Esophageal narrowing or stricturing that will not allow a standard 9 mm upper endoscopy scope to pass~* Cancer in the esophagus, stomach, or intestine~* Previous esophageal surgery~* Esophageal varices (dilated blood vessels in the esophagus)~* Current use of blood thinners like Plavix or Coumadin that are not stopped prior to endoscopy procedures~* Any corticosteroid exposure within the 4 weeks prior to their baseline endoscopic exam. Exclusionary corticosteroid exposure is defined as any swallowed topical steroids for EoE or systemic steroids for any condition within the four weeks prior to the baseline endoscopy. Corticosteroids used for asthma or intranasal corticosteroids are not an exclusion and are allowable.~* Pregnancy~* Inability to read or understand English

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral Viscous Budesonide (OVB) (Type: ACTIVE_COMPARATOR): Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
- Active Fluticasone MDI (Type: ACTIVE_COMPARATOR): Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Agrees to use an acceptable method of contraception for the duration of the study~* Subject has completed the 24-week treatment period in the antecedent study, ALK3831-A303, within 7 days~* Additional criteria may apply~Exclusion Criteria:~* Subject is currently taking medications that are contraindicated with olanzapine use or exhibit drug-interaction potential with olanzapine~* Subject has a positive test for drugs of abuse at study entry~* Subject is pregnant, planning to become pregnant, or breastfeeding during the study~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Oral tablet, daily dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Has met diagnostic criteria for HSDD for at least 6 months~* Is willing and able to understand and comply with all study requirements~* Has a normal pelvic examination at screening~Main Exclusion Criteria:~* Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results~* Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bremelanotide (BMT/BMT) (Type: EXPERIMENTAL): (Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks
- Placebo (PBO/BMT) (Type: PLACEBO_COMPARATOR): (Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signing of letter of consent under written information.~* Men and women with serum glucose of ≥126 and \<400 mg / dl and / or HbA1c ≥6.5% and \<10%.~* Age between 30 and 60 years.~* BMI between 25 - 39.9 kg / m2.~* With or without pharmacological treatment with oral hypoglycemic agents or insulin~* Stable body weight during the last 3 months (± 5%).~* Women in the follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of the laboratory tests~* Women who do not expect to be pregnant within the next 3 months.~Exclusion Criteria:~* Physical or mental incapacity that makes it impossible to carry out the intervention.~* Uncontrolled thyroid disease~* Women with suspicion or confirmation of pregnancy.~* Women who are breastfeeding.~* Hepatic disease or elevation to double the upper normal value of TGO and TGP.~* Diagnosis of renal insufficiency or creatinine\> 1.5 mg / dL or glomerular filtration rate \<60 mL / min).~* Known hypersensitivity to calcined magnesia or Guazuma ulmifolia and / or Tecoma stans.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
- Guazuma ulmifolia plus Tecoma stans (Type: EXPERIMENTAL): The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following hematologic malignancies:~  * Acute myeloid leukemia (AML), meeting 1 of the following criteria:~    * AML beyond first complete remission (CR1)~   * Refractory AML~   * AML arising from myelodysplastic syndromes (MDS)~   * Secondary AML~ * MDS~    * Refractory anemia with excess blasts with \> 10% blasts in bone marrow~ * Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:~    * ALL in CR1 with 1 of the following high-risk features:~      * Philadelphia chromosome (Ph)-positive disease~     * Less than 1 year of age at diagnosis~     * Cytogenetic abnormalities involving chromosome 11q23~   * ALL beyond CR1~   * Refractory ALL~ * Chronic myeloid leukemia beyond first chronic phase~ * Chronic myelomonocytic leukemia~ * Chronic lymphocytic leukemia~    * Stage III-IV disease~   * Does not meet criteria for other bone marrow transplantation (BMT) studies~ * Myeloproliferative disorders~    * Ph-negative disease~ * Hodgkin's or non-Hodgkin's lymphoma~    * Chemotherapy-resistant disease~ * Paroxysmal nocturnal hemoglobinuria with life-threatening thrombosis~ * Multiple myeloma~    * Stage II or III disease~* Very high-risk disease~  * Having an unrelated donor is considered a high-risk condition~* Meets medical criteria for myeloablative BMT for the Sidney Kimmel Comprehensive Cancer Center~* Bone marrow donor available, meeting 1 of the following criteria:~  * Genotypically HLA-identical sibling~ * Phenotypically matched first-degree relative~ * Unrelated donor molecularly matched at HLA-A, -B, -C, -DRB1, and -DQB1~PATIENT CHARACTERISTICS:~Age~* 6 months to 65 years~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* No concurrent dexamethasone as an antiemetic during immunosuppression therapy~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No concurrent immunosuppressants until ≥ 24 hours after the completion of cyclophosphamide (post-transplantation)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bone marrow transplant (Type: EXPERIMENTAL): Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Based on medical history and previous examination, no gastrointestinal complaints can be defined~* Age between 18 and 65 years~* BMI between 18 and 25 kg/m2 and a weight of at least 50 kilograms~* Women in fertile age (\<55 years old) must use contraception or be postmenopausal for at least two years~Exclusion Criteria:~* History of severe or chronic cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol~* Use of medication, including vitamin and iron supplementation, except oral contraceptives, within 14 days prior to start of the study~* Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study~* Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgment of the principle investigator)~* Dieting (for example lactose-free, gluten-free, caloric-restrictive, vegetarian or vegan, macrobiotic diet)~* Pregnancy, lactation~* High alcohol consumption (\>15 alcoholic consumptions per week)~* Smoking/ Using drugs of abuse~* Self-admitted HIV-positive state~* Known allergic reaction to peppermint~* High intake of caffeine (\>8 cups coffee a day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tempocol-ColoPulse® (Type: EXPERIMENTAL): Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
- Tempocol® (Type: ACTIVE_COMPARATOR): Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have histologically or cytologically confirmed advanced or metastatic Small Cell Lung Cancer (SCLC) with documented first disease progression during or following front-line platinum-based systemic regimen~* Tumor must have high Delta-like protein 3 (DLL3) expression defined as having ≥ 75% tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.~* Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.~* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.~Exclusion Criteria:~* Participant has a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class (NYHA) III - IV within 6 months prior to their first dose of study drug.~* Participant has known leptomeningeal metastases.~* Participant has received more than one prior systemic therapy regimen for SCLC.~* Participant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.~* Participant has a history of active malignancies other than SCLC within the past 2 years prior to study entry, with the exception of in situ cancer which was curatively treated.~* Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rovalpituzumab tesirine (Type: EXPERIMENTAL): Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered.
- Topotecan (Type: ACTIVE_COMPARATOR): Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m\^2 on Days 1 to 5 of each 21-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete